The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | The scope for liquid biopsies in colorectal cancer
John Strickler, MD, Duke University, Durham, NC, discusses how the current standard for colorectal biopsy involves tissue samples. The advantages of circulating tumor DNA (ctDNA) include the evaluation of heterogenous aberrations that may be missed in a tissue sample. Liquid biopsies can assess all lesions concurrently. Furthermore, acquiring a liquid biopsy is less invasive and only requires a blood sample. Liquid biopsy acts as a great accompanying tool to tissue biopsies for detecting acquired of heterogenous variants of GI cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
